Delivers pure oxygen under pressure to briefly trigger the body's repair programs. Best proven for healing stubborn wounds; promising but unproven for healthy aging, where early findings on longer chromosome caps, clearance of worn-out cells, sharper thinking, and younger skin rest on small studies from one commercially tied group. Costly and time-consuming, with common ear and vision effects. (Full Review)
| Marker | Target | Why |
|---|---|---|
| hs-CRP | < 1.0 mg/L | Tracks systemic inflammation, a target of the therapy |
| Fasting glucose | 70–85 mg/dL | Safety marker; HBOT can provoke hypoglycemia |
| HbA1c | < 5.4% | Average glucose control and hypoglycemia risk |
| Refraction / visual acuity | Stable from baseline | Detects reversible myopia and cataract progression |
| FEV1 | ≥ 80% of predicted | Screens for air-trapping lung disease |
| Hemoglobin | 13–15 g/dL | Oxygen delivery depends on red-cell status; flags anemia |
| Biological-age / telomere panel | Improvement or stability vs baseline | Optional tracking of longevity surrogate outcomes |
Cadence: Baseline, mid-course (around session 20–30), and at course completion; glucose every session for people with diabetes; re-assess success markers at course end and a few months later.